CGTLive’s Weekly Rewind – February 10, 2023

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Tecartus Shows Overall Survival Benefit for R/R B-ALL in 3-Year Follow-up Data

The updated data included a median overall survival of 26 months after treatment with brexu-cel.

2. Sham Mailankody, MBBS, on Further Research With ALLO-715

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

3. IND for Gene Replacement Therapy for Inherited Retinal Dystrophy Cleared by FDA

The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.

4. Raj Mehra, PhD, and Krishna Subramanian, PhD, on Parkinson Disease Gene Therapy Mouse Studies

Mehra and Subramanian discussed preclinical safety studies with the gene therapy SLS-004 and plans for future research.

5. First Patient with B-cell Lymphoma Dosed With Allogeneic NK CAR T Therapy

The FDA cleared Century’s IND for CNTY-101 in August 2022.